Newsroom
Verantos Announces Breakthrough in Non-alcoholic Steatohepatitis Real-world Evidence
Verantos, the market leader in high-validity real-world evidence generation, announced a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH), achieving phenotyping accuracy exceeding 90%.
Read at the original outletAll news